Gemer O, Arie A Ben, Levy T, Gdalevich M, Lorian M, Barak F, Anteby E, Lavie O
Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel.
Eur J Surg Oncol. 2007 Jun;33(5):644-7. doi: 10.1016/j.ejso.2007.01.009. Epub 2007 Feb 20.
To quantify the relative risk associated with lymphvascular space involvement (LVSI) on outcome measures in patients with apparent stage I endometrial cancer.
Six hundred and ninety nine consecutive patients with endometrial carcinoma apparent stage I, who underwent surgery in one of four gynecological oncology centers in Israel, comprised the study population. Forty cases with and 659 without LVSI were followed for a median time of 39 months. Recurrence free, disease specific and overall survival was compared between the two groups. The effect of LVSI, adjusted for other clinical and histo-pathological prognostic factors, was assessed by multivariate analysis.
The univariate Kaplan-Meier procedure for survival analysis showed that patients with LVSI had lower recurrence free survival (p=0.0003), worse disease specific (p=0.0007) and overall survival (p<0.0001). Cox proportional hazards model demonstrated a trend toward shorter recurrence free survival (HR=2.0, 95% CI 0.9, 4.5; p=0.08), a worse disease specific survival (HR=2.8, 95% CI 1.1, 7.4; p=0.04) and decreased overall survival (HR=2.0, 95% CI 1.1, 3.8; p=0.03) in cases with LVSI.
In patients with apparent stage I endometrial cancer the presence of LVSI, an independent poor prognostic factor, is associated with a two fold increased risk of death. The presence of LVSI warrants consideration when deciding upon post operative management.
量化与Ⅰ期子宫内膜癌患者结局指标相关的淋巴管间隙浸润(LVSI)的相对风险。
699例连续的Ⅰ期子宫内膜癌患者构成了研究人群,这些患者在以色列四个妇科肿瘤中心之一接受了手术。40例有LVSI和659例无LVSI的患者被随访了39个月的中位时间。比较两组的无复发生存率、疾病特异性生存率和总生存率。通过多因素分析评估LVSI的影响,并对其他临床和组织病理学预后因素进行校正。
单因素生存分析的Kaplan-Meier法显示,有LVSI的患者无复发生存率较低(p = 0.0003),疾病特异性生存率较差(p = 0.0007),总生存率较差(p < 0.0001)。Cox比例风险模型显示,有LVSI的患者无复发生存期有缩短趋势(HR = 2.0,95% CI 0.9,4.5;p = 0.08),疾病特异性生存率较差(HR = 2.8,95% CI 1.1,7.4;p = 0.04),总生存率降低(HR = 2.0,95% CI 1.1,3.8;p = 0.03)。
在Ⅰ期子宫内膜癌患者中,LVSI的存在是一个独立的不良预后因素,与死亡风险增加两倍相关。在决定术后治疗方案时,LVSI的存在值得考虑。